Sotio

SOTIO a.s.[1] is a biotechnology company based in Prague, Czech Republic. The company was founded in 2010 and since 2012 it is part of PPF Group owned by Petr Kellner.[2] The CEO of the company is Radek Špíšek, who has been with the company from its beginning as Chief Scientific Officer.[3] The company focuses on research and development of innovative medicines for cancer.[4][5] Besides European countries, it also operates in the USA, Russia and China.[1] In January 2020, the company announced the founding of its subsidiary in Basel, Switzerland.[6] Sotio opened a laboratory complexes Prague, Czech Republic and Beijing,[7][8] China where it produces treatments for people suffering from oncological diseases.[9]

Sotio
Industryhealthcare, biotechnology
Founded19. 4. 2010
FounderHekto B.V.
Headquarters
Prague
,
Czech Republic
Total assets250 mio EUR (2018)
OwnerPPF Group N.V.
Websitehttps://www.sotio.com/

Sotio is currently testing six oncology products at different stages of development.[10] In 2011, the first clinical trial with active cellular immunotherapy DCVAC started, focusing on prostate cancer, ovarian cancer[11][12] and lung cancer.[5][13]

Sotio has its own scientific research and development and also collaborates with other partners.[14] In recent years, Sotio and PPF have focused on investing in a number of biotechnology companies developing innovative anticancer treatments in Europe and the US. For example, it cooperates with the Swiss NBE-Therapeutics on the development of novel antibody-drug conjugate products (ADC),[15] with its affiliate Cytune Pharma on developing novel IL-15-based immunotherapies for the treatment of cancer[16] and with the Lead Discovery Center and the Max Planck Society on an oncology program addressing a novel target in tumor metabolism.[17][18]

In August 2018, Sotio acquired Cytune Pharma.[19] and announced to continue development of the company's lead program SO-C101 (RLI-15) which is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Ra. It is a novel immunotherapeutic approach with potential applications in a variety of oncology indications. The first clinical trial for the program was launched in summer 2019.[20][21]

References
  1. "The company - About us - Sotio a.s." sotio.com.
  2. "Czech PPF Group biotech firms begin trials to extend lives of cancer patients". Radio Prague International. Retrieved 2020-01-23.
  3. "Holding Management". Sotio.com. Retrieved 24 July 2019.
  4. Helene (2019-12-23). "SOTIO Arms Dendritic Cells for Immunotherapy Against Cancer". WuXi XPress: for WuXi news and R&D insights. Retrieved 2020-01-23.
  5. "Kellnerova firma Sotio zahájila testy léku na rakovinu plic". E15.cz.
  6. "SOTIO to accelerate Pipeline Products development in Switzerland". www.biospectrumasia.com. Retrieved 2020-01-23.
  7. AG, BIOCOM. "Sotio on track for 2nd Phase III trial". european-biotechnology.com. Retrieved 2020-01-23.
  8. "SOTIO opens state-of-the-art laboratory in Chinese Beijing to produce therapeutical products against cancer diseases | Sotio". www.sotio.com. Retrieved 2020-01-23.
  9. "Firma Sotio otevřela v Číně laboratoř, má pomoci proti rakovině". mednes.cz.
  10. "PPF/SOTIO Biotech Pipeline | Sotio". www.sotio.com. Retrieved 2020-01-23.
  11. "SOTIO's DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Can". PharmiWeb.com. Retrieved 2020-01-23.
  12. "Kellnerova firma začala test léku na rakovinu vaječníků". Aktuálně.cz - Víte co se právě děje.
  13. Zuzana Kubátová (6 January 2015). "Kellnerova firma začíná testovat už třetí lék, tentokrát na nádory plic". iDNES.cz.
  14. "Czech billionaire Kellner's PPF Group expands in biotech with Autolus stake". Reuters. 2019-09-16. Retrieved 2020-01-23.
  15. "SOTIO expands collaboration with NBE Therapeutics Startupticker.ch | The Swiss Startup News channel". www.startupticker.ch. Retrieved 2020-01-23.
  16. "PPF's Biotech Divisions Report Advances In Cancer Research". praguebusinessjournal.com. Retrieved 2020-01-23.
  17. "LDC and SOTIO License and Collaboration Agreement". www.firstwordpharma.com. Retrieved 2020-01-23.
  18. plc, London Stock Exchange (2017-04-11). "SOTIO a.s.: LDC and SOTIO License and Collaboration Agreement". GlobeNewswire News Room. Retrieved 2020-01-23.
  19. Letter, The Pharma. "SOTIO completes acquisition of Cytune Pharma". www.thepharmaletter.com. Retrieved 2018-09-18.
  20. "SOTIO, biotech major acquires Cytune Pharma". ehealth.eletsonline.com. Retrieved 2018-09-18.
  21. "PPF Group & Sotio complete acquisition of Cytune". EPM Magazine. 2018-08-31. Retrieved 2018-09-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.